Skip to main content
Erschienen in: Der Nervenarzt 12/2017

16.10.2017 | Multiple Sklerose | Leitthema

Multiple Sklerose im Kindes- und Jugendalter

Komplex, chronisch, differenziert

verfasst von: Dr. A. Blaschek, P. Huppke, T. Kümpfel, W. Müller-Felber, K. Rostasy

Erschienen in: Der Nervenarzt | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die pädiatrische multiple Sklerose (MS) gehört zu den wichtigen erworbenen neurologischen Erkrankungen des Kindesalters, die einer frühzeitigen Erkennung, Diagnose und Behandlung bedürfen. Der Beitrag gibt eine aktuelle Übersicht über Ätiologie und Pathogenese, Diagnose, klinische Symptomatik und Therapie im Kindesalter. Trotz der in den ersten Jahren deutlich niedrigeren Behinderungsprogression im Vergleich zu Erwachsenen ist eine frühzeitige verlaufsmodifizierende Therapie indiziert.
Literatur
2.
Zurück zum Zitat Banwell B, Bar-Or A, Arnold DL, Sadovnick D, Narayanan S, McGowan M, O’Mahony J, Magalhaes S, Hanwell H, Vieth R, Tellier R, Vincent T, Disanto G, Ebers G, Wambera K, Connolly MB, Yager J, Mah JK, Booth F, Sebire G, Callen D, Meaney B, Dilenge ME, Lortie A, Pohl D, Doja A, Venketaswaran S, Levin S, Macdonald EA, Meek D, Wood E, Lowry N, Buckley D, Yim C, Awuku M, Cooper P, Grand’maison F, Baird JB, Bhan V, Marrie RA (2011) Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 10(5):436–445. https://doi.org/10.1016/S1474-4422(11)70045-X CrossRefPubMed Banwell B, Bar-Or A, Arnold DL, Sadovnick D, Narayanan S, McGowan M, O’Mahony J, Magalhaes S, Hanwell H, Vieth R, Tellier R, Vincent T, Disanto G, Ebers G, Wambera K, Connolly MB, Yager J, Mah JK, Booth F, Sebire G, Callen D, Meaney B, Dilenge ME, Lortie A, Pohl D, Doja A, Venketaswaran S, Levin S, Macdonald EA, Meek D, Wood E, Lowry N, Buckley D, Yim C, Awuku M, Cooper P, Grand’maison F, Baird JB, Bhan V, Marrie RA (2011) Clinical, environmental, and genetic determinants of multiple sclerosis in children with acute demyelination: a prospective national cohort study. Lancet Neurol 10(5):436–445. https://​doi.​org/​10.​1016/​S1474-4422(11)70045-X CrossRefPubMed
3.
Zurück zum Zitat Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, Karenfort M, Selch C, Hausler M, Eisenkolbl A, Salandin M, Gruber-Sedlmayr U, Blaschek A, Kraus V, Leiz S, Finsterwalder J, Gotwald T, Kuchukhidze G, Berger T, Reindl M, Rostasy K (2015) Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatr 86(3):265–272. https://doi.org/10.1136/jnnp-2014-308346 CrossRef Baumann M, Sahin K, Lechner C, Hennes EM, Schanda K, Mader S, Karenfort M, Selch C, Hausler M, Eisenkolbl A, Salandin M, Gruber-Sedlmayr U, Blaschek A, Kraus V, Leiz S, Finsterwalder J, Gotwald T, Kuchukhidze G, Berger T, Reindl M, Rostasy K (2015) Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatr 86(3):265–272. https://​doi.​org/​10.​1136/​jnnp-2014-308346 CrossRef
4.
Zurück zum Zitat Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I (2015) Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 14(3):263–273CrossRefPubMed Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I (2015) Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 14(3):263–273CrossRefPubMed
6.
Zurück zum Zitat Fragoso YD, Alves-Leon SV, Barreira AA, Callegaro D, Brito Ferreira ML, Finkelsztejn A, Gomes S, Magno Goncalves MV, Moraes Machado MI, Marques VD, Cunha Matta AP, Papais-Alvarenga RM, Pereira ASL, Tauil CB (2015) Fingolimod prescribed for the treatment of multiple sclerosis in patients younger than Age 18 years. Pediatr Neurol 53(2):166–168CrossRefPubMed Fragoso YD, Alves-Leon SV, Barreira AA, Callegaro D, Brito Ferreira ML, Finkelsztejn A, Gomes S, Magno Goncalves MV, Moraes Machado MI, Marques VD, Cunha Matta AP, Papais-Alvarenga RM, Pereira ASL, Tauil CB (2015) Fingolimod prescribed for the treatment of multiple sclerosis in patients younger than Age 18 years. Pediatr Neurol 53(2):166–168CrossRefPubMed
7.
Zurück zum Zitat Ghezzi A, Pozzilli C, Grimaldi LM, Brescia Morra V, Bortolon F, Capra R, Filippi M, Moiola L, Rocca MA, Rottoli M, Sarchielli P, Zaffaroni M, Comi G (2010) Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 75(10):912–917CrossRefPubMed Ghezzi A, Pozzilli C, Grimaldi LM, Brescia Morra V, Bortolon F, Capra R, Filippi M, Moiola L, Rocca MA, Rottoli M, Sarchielli P, Zaffaroni M, Comi G (2010) Safety and efficacy of natalizumab in children with multiple sclerosis. Neurology 75(10):912–917CrossRefPubMed
8.
Zurück zum Zitat Hennes EMBM, Schanda K et al (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89(9):900–908CrossRefPubMed Hennes EMBM, Schanda K et al (2017) Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome. Neurology 89(9):900–908CrossRefPubMed
9.
Zurück zum Zitat Huppke B, Ellenberger D, Rosewich H, Friede T, Gartner J, Huppke P (2014) Clinical presentation of pediatric multiple sclerosis before puberty. Eur J Neurol 21(3):441–446CrossRefPubMed Huppke B, Ellenberger D, Rosewich H, Friede T, Gartner J, Huppke P (2014) Clinical presentation of pediatric multiple sclerosis before puberty. Eur J Neurol 21(3):441–446CrossRefPubMed
10.
Zurück zum Zitat Huppke P, Hummel H, Ellenberger D, Pfeifenbring S, Stark W, Huppke B, Bruck W, Gartner J (2015) JC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity. Mult Scler 21(4):382–387CrossRefPubMed Huppke P, Hummel H, Ellenberger D, Pfeifenbring S, Stark W, Huppke B, Bruck W, Gartner J (2015) JC virus antibody status in a pediatric multiple sclerosis cohort: prevalence, conversion rate and influence on disease severity. Mult Scler 21(4):382–387CrossRefPubMed
12.
Zurück zum Zitat Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, Ghezzi A, Hintzen R, Kornberg A, Pohl D, Rostasy K, Tenembaum S, Wassmer E, International Pediatric Multiple Sclerosis Study G (2013) International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19:1261–1267CrossRefPubMed Krupp LB, Tardieu M, Amato MP, Banwell B, Chitnis T, Dale RC, Ghezzi A, Hintzen R, Kornberg A, Pohl D, Rostasy K, Tenembaum S, Wassmer E, International Pediatric Multiple Sclerosis Study G (2013) International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 19:1261–1267CrossRefPubMed
13.
Zurück zum Zitat Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRefPubMed Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRefPubMed
14.
Zurück zum Zitat Mikaeloff Y, Caridade G, Tardieu M, Suissa S, KIDSEP study group (2007) Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 130(10):2589–2595CrossRefPubMed Mikaeloff Y, Caridade G, Tardieu M, Suissa S, KIDSEP study group (2007) Parental smoking at home and the risk of childhood-onset multiple sclerosis in children. Brain 130(10):2589–2595CrossRefPubMed
15.
Zurück zum Zitat Neuteboom RF, Boon M, Catsman Berrevoets CE, Vles JS, Gooskens RH, Stroink H, Vermeulen RJ, Rotteveel JJ, Ketelslegers IA, Peeters E, Poll-The BT, De Rijk-Van Andel JF, Verrips A, Hintzen RQ (2008) Prognostic factors after a first attack of inflammatory CNS demyelination in children. Neurology 71(13):967–973CrossRefPubMed Neuteboom RF, Boon M, Catsman Berrevoets CE, Vles JS, Gooskens RH, Stroink H, Vermeulen RJ, Rotteveel JJ, Ketelslegers IA, Peeters E, Poll-The BT, De Rijk-Van Andel JF, Verrips A, Hintzen RQ (2008) Prognostic factors after a first attack of inflammatory CNS demyelination in children. Neurology 71(13):967–973CrossRefPubMed
16.
Zurück zum Zitat Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRefPubMedPubMedCentral Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, Deluca GC, Herrera BM, Chao MJ, Sadovnick AD, Ebers GC, Knight JC (2009) Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. Plos Genet 5(2):e1000369CrossRefPubMedPubMedCentral Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dyment DA, Deluca GC, Herrera BM, Chao MJ, Sadovnick AD, Ebers GC, Knight JC (2009) Expression of the multiple sclerosis-associated MHC class II allele HLA-DRB1*1501 is regulated by vitamin D. Plos Genet 5(2):e1000369CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Reinhardt K, Weiss S, Rosenbauer J, Gartner J, von Kries R (2014) Multiple sclerosis in children and adolescents: incidence and clinical picture – new insights from the nationwide German surveillance (2009–2011). Eur J Neurol 21(4):654–659CrossRefPubMed Reinhardt K, Weiss S, Rosenbauer J, Gartner J, von Kries R (2014) Multiple sclerosis in children and adolescents: incidence and clinical picture – new insights from the nationwide German surveillance (2009–2011). Eur J Neurol 21(4):654–659CrossRefPubMed
19.
Zurück zum Zitat Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, Debouverie M, Brochet B, Lebrun-Frenay C, Pelletier J, Moreau T, Lubetzki C, Vermersch P, Roullet E, Magy L, Tardieu M, Suissa S, Confavreux C (2007) Natural history of multiple sclerosis with childhood onset. N Engl J Med 356(25):2603–2613CrossRefPubMed Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, Debouverie M, Brochet B, Lebrun-Frenay C, Pelletier J, Moreau T, Lubetzki C, Vermersch P, Roullet E, Magy L, Tardieu M, Suissa S, Confavreux C (2007) Natural history of multiple sclerosis with childhood onset. N Engl J Med 356(25):2603–2613CrossRefPubMed
20.
Zurück zum Zitat Rostasy K, Bajer-Kornek B, Venkateswaran S, Hemingway C, Tardieu M (2016) Differential diagnosis and evaluation in pediatric inflammatory demyelinating disorders. Neurology 87(9 Supplement 2):S28–S37CrossRefPubMed Rostasy K, Bajer-Kornek B, Venkateswaran S, Hemingway C, Tardieu M (2016) Differential diagnosis and evaluation in pediatric inflammatory demyelinating disorders. Neurology 87(9 Supplement 2):S28–S37CrossRefPubMed
21.
Zurück zum Zitat Sadovnick AD, Yee IM, Ebers GC, Risch NJ (1998) Effect of age at onset and parental disease status on sibling risks for MS. Neurology 50(3):719–723CrossRefPubMed Sadovnick AD, Yee IM, Ebers GC, Risch NJ (1998) Effect of age at onset and parental disease status on sibling risks for MS. Neurology 50(3):719–723CrossRefPubMed
22.
Zurück zum Zitat Stark W, Huppke P, Gartner J (2008) Paediatric multiple sclerosis: the experience of the German centre for multiple sclerosis in childhood and adolescence. J Neurol 255(S6):119–122CrossRefPubMed Stark W, Huppke P, Gartner J (2008) Paediatric multiple sclerosis: the experience of the German centre for multiple sclerosis in childhood and adolescence. J Neurol 255(S6):119–122CrossRefPubMed
23.
Zurück zum Zitat van Pelt ED, Mescheriakova JY, Makhani N, Ketelslegers IA, Neuteboom RF, Kundu S, Broer L, Janssens C, Catsman-Berrevoets CE, van Duijn CM, Banwell B, Bar-Or A, Hintzen RQ (2013) Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology 81(23):1996–2001CrossRefPubMed van Pelt ED, Mescheriakova JY, Makhani N, Ketelslegers IA, Neuteboom RF, Kundu S, Broer L, Janssens C, Catsman-Berrevoets CE, van Duijn CM, Banwell B, Bar-Or A, Hintzen RQ (2013) Risk genes associated with pediatric-onset MS but not with monophasic acquired CNS demyelination. Neurology 81(23):1996–2001CrossRefPubMed
24.
25.
Zurück zum Zitat Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B (2014) Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol 13(9):936–948CrossRefPubMedPubMedCentral Waldman A, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M, Banwell B (2014) Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research. Lancet Neurol 13(9):936–948CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, Kuntz N, Ness J, Chabas D, Strober J, McDonald J, Belman A, Milazzo M, Gorman M, Weinstock-Guttman B, Rodriguez M, Oksenberg JR, James JA, US Pediatric MS Network (2011) Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 76(23):1989–1995CrossRefPubMedPubMedCentral Waubant E, Mowry EM, Krupp L, Chitnis T, Yeh EA, Kuntz N, Ness J, Chabas D, Strober J, McDonald J, Belman A, Milazzo M, Gorman M, Weinstock-Guttman B, Rodriguez M, Oksenberg JR, James JA, US Pediatric MS Network (2011) Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 76(23):1989–1995CrossRefPubMedPubMedCentral
Metadaten
Titel
Multiple Sklerose im Kindes- und Jugendalter
Komplex, chronisch, differenziert
verfasst von
Dr. A. Blaschek
P. Huppke
T. Kümpfel
W. Müller-Felber
K. Rostasy
Publikationsdatum
16.10.2017
Verlag
Springer Medizin
Erschienen in
Der Nervenarzt / Ausgabe 12/2017
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-017-0422-z

Weitere Artikel der Ausgabe 12/2017

Der Nervenarzt 12/2017 Zur Ausgabe

Mitteilungen der DGPPN

Mitteilungen der DGPPN 12/2017

Passend zum Thema

ANZEIGE
OnSite Advertorial Multiple Sklerose
Service mit Mehrwert

Services in der MS-Therapie für Neurolog*innen und Betroffene

Diagnose und Therapie der MS können für Patient*innen und Neurolog*innen mit Herausforderungen einhergehen [1,2]. Mit umfangreichen Servicemaßnahmen klärt Biogen Ärztinnen und Ärzte über mögliche Therapieoptionen auf und unterstützt diese bei der Fortbildung sowie Betroffene im Alltag.